Gemcitabine and taxane combinations in non-small-cell lung cancer

Clinical Lung Cancer

Volumn 2, Issue SUPPL. 1, 2000, Pages

  Natale, R B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Docetaxel; Gemcitabine; Paclitaxel; Taxanes; Weekly administration

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TAXANE DERIVATIVE;

ANEMIA; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; STANDARD; THROMBOCYTOPENIA;

EID: 0034463947     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2000.s.009     Document Type: Article

References (28)

1. Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer
2. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)
3. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
4. Defining the role of paclitaxel in lung cancer: Summary of recent studies and implications for future directions
5. Gemcitabine: Single-agent and combination therapy in non-small cell lung cancer
6. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
7. A phase I study of Taxotere® (T) and Gemzar® (G) in patients with advanced solid tumors
8. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies
9. Second-line chemotherapy with weekly gemcitabine (GEM) and monthly docetaxel (DOC) in patients (Pts) with non-small cell lung cancer (NSCLC): A phase II study
10. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial
11. Docetaxel and gemcitabine in metastatic non-small-cell lung cancer (NSCLC). A phase II study. Preliminary feasibility report
12. A phase II study of docetaxel (D) and gemcitabine (G) combination in patients (Pts) with non-small cell lung cancer (NSCLC)
13. Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: A preliminary analysis of a multicenter randomized phase II trial
14. Phase I clinical and pharmacokinetic study of docetaxel in combination with two gemcitabine infusion schedules
15. A comparison of two schedules of docetaxel (D) in combination with gemcitabine (G) given every other week
16. Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: A multicenter phase II study
17. A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients
18. Results of a phase II study with Taxol (paclitaxel) and Gemzar (gemcitabine) in metastatic non-small cell lung cancer (NSCLC)
19. Phase II study of gemcitabine and paclitaxel in metastatic non-small cell lung cancer
20. Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: A phase III randomized study. Preliminary results
21. A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non-small cell lung cancer: A preliminary analysis
22. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: Results of a phase I/II trial
23. Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer
24. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer
25. Weekly paclitaxel and carboplatin in non-small cell lung cancer
26. A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors
27. A phase II study of paclitaxel (P) and gemcitabine (G) in patients with advanced non small cell lung cancer - A Hoosier Oncology Group study
28. Docetaxel (Taxotere) and gemcitabine in combination therapy